Drugs / PYRROTINI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04767828 | May 2020 → Jun 2022 | thrombotic thrombocytopenic purpura | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyrrotini | “Pyrrotini: 400 mg once a day, oral” NCT04767828 ↗ |
| Route | Oral | “Pyrrotini: 400 mg once a day, oral” NCT04767828 ↗ |